Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hu Li Health Media To Merge With Kangshi Media

This article was originally published in PharmAsia News

Executive Summary

Inside sources at Hu Li Health Media recently revealed that the firm will be merging with Kangshi Media, China's third largest health care media player. The acquisition will put Hu Li on track for an overseas listing by the first half of 2009. In Q1 this year, the company acquired three national and five local hospital LCD operators, adding more than 4,000 LCD screens to its existing 20,000. Its third round of financing worth some $60 million will be used to increase the LCD screen density in grade three and above hospitals. According to AC Nielsen, hospital advertising in China attracts more than 1 billion views annually. In the next five years, the multimedia sector is expected to occupy 20-30 percent of the entire advertising business to hit 50 billion yuan. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel